Brief: Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 And Extends Cash Runway
20/01/2026 12:12
Jan 20 (Reuters) - Boundless Bio Inc BOLD.O: BOUNDLESS BIO ADVANCES NOVEL KINESIN DEGRADER PROGRAM BBI-940 AND EXTENDS CASH RUNWAY BOUNDLESS BIO INC: BBI-940 IND ACCEPTED; INITIATION OF FIRST-IN-HUMAN CLINICAL TRIAL ON TRACK FOR FIRST HALF OF 2026 BOUNDLESS BIO INC: PORTFOLIO PRIORITIZATION, INCLUDING DISCONTINUATION OF POTENTIATE TRIAL, EXTENDS OPERATING RUNWAY INTO H2 2028 Source text: ID:nGNXb6Yd94 Further company coverage: BOLD.O (Reporting by Kunal Das) ((Kunal.Das2@thomsonreuters.com;))
Recent news on Boundless Bio
See all newsBoundless Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Boundless Bio Inc expected to post a loss of 58 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Bath & Body Works, Avis Budget, Cerebras
U.S. STOCKS ON THE MOVE-Boundless Bio, Galectin, UniQure
Boundless Bio soars on merger with Serapha